FTC Challenges Illumina's $1B DNA Sequencing Buy
The Federal Trade Commission launched a merger challenge Tuesday accusing Illumina of trying to "unlawfully maintain" a monopoly over next-generation DNA sequencing systems in the U.S., saying the company is seeking...To view the full article, register now.
Already a subscriber? Click here to view full article